Twist Bioscience Corp (TWST)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $7.40B
Last updated: Nov 17, 2026 at 11:06 AM ET
Twist Bioscience Corp (TWST) Earnings: Report Dates and Results
Twist Bioscience (TWST) is expected to report earnings on Feb 1, 2027. In the quarter ended Sep 30, 2026, Twist Bioscience reported EPS of -$0.32, above the -$0.43 estimate. It beat the EPS estimate in 5 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
TWST has an expected report date of Feb 1, 2027.
TWST Earnings Call
The latest TWST earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 33 quarters below that had an estimate, TWST beat 21, missed 11 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $126.64M, up 27.9% from $99.01M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.32 | -$0.43 | N/A | +25.58% | Beat | N/A | 4 | 0 up, 1 down | Nov 12, 2026 | $126.64M |
| Jun 30, 2026 | -$0.56 | -$0.50 | N/A | -12.00% | Miss | N/A | 2 | 0 up, 0 down | Aug 3, 2026 | $118.38M |
| Mar 31, 2026 | -$0.60 | -$0.53 | -$0.53 - -$0.53 | -13.21% | Miss | N/A | 1 | 0 up, 0 down | May 4, 2026 | $110.72M |
| Dec 31, 2025 | -$0.50 | -$0.52 | -$0.52 - -$0.52 | +3.85% | Beat | N/A | 1 | 0 up, 0 down | Feb 2, 2026 | $103.70M |
| Sep 30, 2025 | -$0.45 | -$0.50 | -$0.50 - -$0.50 | +10.00% | Beat | N/A | 1 | 2 up, 1 down | Nov 14, 2025 | $99.01M |
| Jun 30, 2025 | -$0.47 | -$0.57 | -$0.61 - -$0.52 | +17.54% | Beat | N/A | 3 | 1 up, 3 down | Aug 4, 2025 | $96.06M |
| Mar 31, 2025 | -$0.66 | -$0.56 | -$0.59 - -$0.51 | -17.86% | Miss | N/A | 5 | 2 up, 0 down | May 5, 2025 | $92.79M |
| Dec 31, 2024 | -$0.53 | -$0.63 | -$0.65 - -$0.62 | +15.87% | Beat | N/A | 2 | 1 up, 0 down | Feb 3, 2025 | $88.71M |
| Sep 30, 2024 | -$0.59 | -$0.69 | -$0.73 - -$0.67 | +14.49% | Beat | N/A | 3 | 0 up, 1 down | Nov 18, 2024 | $84.71M |
| Jun 30, 2024 | -$0.70 | -$0.77 | -$0.81 - -$0.73 | +9.09% | Beat | N/A | 10 | 0 up, 0 down | Aug 2, 2024 | $81.46M |
| Mar 31, 2024 | -$0.79 | -$0.81 | -$0.86 - -$0.76 | +2.47% | Beat | N/A | 9 | 0 up, 1 down | May 2, 2024 | $75.30M |
| Dec 31, 2023 | -$0.75 | -$0.77 | -$0.82 - -$0.72 | +2.60% | Beat | N/A | 9 | 1 up, 0 down | Feb 2, 2024 | $71.50M |
| Sep 30, 2023 | -$0.75 | -$0.86 | -$1.25 - -$0.80 | +12.79% | Beat | N/A | 9 | 0 up, 0 down | Nov 17, 2023 | $66.95M |
| Jun 30, 2023 | -$1.02 | -$1.06 | -$1.23 - -$1.02 | +3.77% | Beat | N/A | 8 | 0 up, 0 down | Aug 4, 2023 | $63.74M |
| Mar 31, 2023 | -$1.06 | -$1.10 | -$1.26 - -$1.02 | +3.64% | Beat | N/A | 9 | 0 up, 0 down | May 5, 2023 | $60.18M |
| Dec 31, 2022 | -$0.81 | -$1.17 | -$1.26 - -$1.05 | +30.77% | Beat | N/A | 7 | 0 up, 0 down | Feb 3, 2023 | $54.24M |
| Sep 30, 2022 | -$1.01 | -$1.13 | -$1.40 - -$1.06 | +10.62% | Beat | N/A | 8 | 0 up, 0 down | Nov 18, 2022 | $57.31M |
| Jun 30, 2022 | -$1.08 | -$1.31 | -$1.40 - -$1.18 | +17.56% | Beat | N/A | 7 | 2 up, 0 down | Aug 5, 2022 | $56.11M |
| Mar 31, 2022 | -$1.02 | -$1.30 | -$1.33 - -$1.19 | +21.54% | Beat | N/A | 7 | 2 up, 0 down | May 5, 2022 | $48.13M |
| Dec 31, 2021 | -$0.96 | -$1.06 | -$1.27 - -$0.95 | +9.43% | Beat | N/A | 8 | N/A | Feb 4, 2022 | $42.02M |
| Sep 30, 2021 | -$0.84 | -$0.79 | -$0.89 - -$0.70 | -6.33% | Miss | N/A | 7 | N/A | Nov 22, 2021 | $37.95M |
| Jun 30, 2021 | -$0.78 | -$0.75 | -$0.77 - -$0.73 | -4.00% | Miss | N/A | 7 | N/A | Aug 6, 2021 | $35.02M |
| Mar 31, 2021 | -$0.78 | -$0.78 | -$0.80 - -$0.72 | 0.00% | In line | N/A | 5 | N/A | May 6, 2021 | $31.20M |
| Dec 31, 2020 | -$0.72 | -$0.77 | -$0.78 - -$0.67 | +6.49% | Beat | N/A | 4 | N/A | Feb 4, 2021 | $28.16M |
| Sep 30, 2020 | -$0.54 | -$0.70 | -$0.77 - -$0.66 | +22.86% | Beat | N/A | 4 | N/A | Nov 23, 2020 | $32.43M |
| Jun 30, 2020 | -$0.67 | -$0.88 | -$0.88 - -$0.55 | +23.86% | Beat | N/A | 3 | N/A | Aug 6, 2020 | $21.21M |
| Mar 31, 2020 | -$0.85 | -$0.75 | -$0.83 - -$0.69 | -13.33% | Miss | N/A | 4 | N/A | May 7, 2020 | $19.30M |
| Dec 31, 2019 | -$1.00 | -$0.83 | -$0.95 - -$0.77 | -20.48% | Miss | N/A | 3 | N/A | Feb 6, 2020 | $17.16M |
| Sep 30, 2019 | -$0.96 | -$0.83 | -$0.87 - -$0.78 | -15.66% | Miss | N/A | 4 | N/A | Dec 11, 2019 | $15.74M |
| Jun 30, 2019 | -$0.92 | -$0.82 | -$0.90 - -$0.76 | -12.20% | Miss | N/A | 4 | N/A | Aug 1, 2019 | $13.60M |
| Mar 31, 2019 | -$0.93 | -$0.97 | -$1.24 - -$0.82 | +4.12% | Beat | N/A | 3 | N/A | Apr 30, 2019 | $13.56M |
| Dec 31, 2018 | -$1.18 | -$0.85 | -$0.94 - -$0.77 | -38.82% | Miss | N/A | 3 | N/A | Feb 7, 2019 | $11.49M |
| Sep 30, 2018 | -$6.59 | -$0.75 | N/A | -778.67% | Miss | N/A | N/A | N/A | Nov 1, 2018 | $8.41M |
| Jun 30, 2018 | -$0.66 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 29, 2018 | $6.54M |
Annual EPS
EPS for the fiscal year ended Sep 30, 2026 was -$1.98, after -$2.11 the year before. It was -$7.25 for the year ended Sep 30, 2018, the oldest of the 9 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Sep 30, 2026 | -$1.98 | N/A |
| Sep 30, 2025 | -$2.11 | N/A |
| Sep 30, 2024 | -$2.83 | N/A |
| Sep 30, 2023 | -$3.64 | N/A |
| Sep 30, 2022 | -$4.07 | N/A |
| Sep 30, 2021 | -$3.12 | N/A |
| Sep 30, 2020 | -$3.06 | N/A |
| Sep 30, 2019 | -$3.99 | N/A |
| Sep 30, 2018 | -$7.25 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,900 words across 15 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 6,852 | 15 | |
| 2026Q2 | Jun 30, 2026 | 5,750 | 15 | |
| 2026Q1 | Mar 31, 2026 | 6,376 | 12 | |
| 2025Q4 | Dec 31, 2025 | 6,412 | 14 | |
| 2025Q3 | Sep 30, 2025 | 5,741 | 15 | |
| 2025Q2 | Jun 30, 2025 | 6,375 | 15 | |
| 2025Q1 | Mar 31, 2025 | 6,405 | 15 | |
| 2024Q4 | Dec 31, 2024 | 7,095 | 16 |
2026Q3 Earnings Call
Opening remarks
Angela Bitting SVP, Corporate Affairs Thank you, operator. Good morning, everyone. I'd like to thank you for joining us for Twist Bioscience's Conference Call to review our fiscal 2026 third quarter financial results and business progress. We issued our financial results press release before the market, and it is available at our website at www.twistbioscience.com. With me on the call today are Dr. Emily Leproust, CEO and Co-Founder of Twist; Adam Laponis, CFO of Twist; and Dr. Patrick Finn, President and COO of Twist. Today, we will discuss our business progress, financial and operational performance as well as growth opportunities. We'll then open the call for questions. We ask that you limit your questions to only one and then requeue as a courtesy to others on the call. This call is being recorded, and the audio portion will be archived in the Investors section of our website and will be available for 2 weeks. During today's presentation, we will make forward-looking statements within the meaning of the U.S. federal securities laws. Forward-looking statements generally relate to future events or future financial or operating performance. Our expectations and beliefs regarding these matters may not materialize, and actual results in financial periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected. These risks include those set forth in the press release we issued earlier today as well as those more fully described in our filings with the Securities and Exchange Commission. The forward-looking statements in this presentation are based on information available to us as of the date hereof, and we disclaim any obligation to update any forward-looking statements, except as required by law. We'll also discuss adjusted EBITDA, a financial measure that does not conform with generally accepted accounting principles. Information may be calculated differently than similar non-GAAP data presented by other companies. When reported, a reconciliation between GAAP and non-GAAP financial measures will be included in our earnings documents, which can be found on the Investors section of our website. With that, I will now turn the call over to our CEO and Co-Founder, Emily Leproust.
Emily Leproust CEO & Co-Founder Thank you, Angela, and good morning, everyone. On Slide 3, you will see that this morning, we reported our 14th quarter of consistent growth with record revenue of $118.4 million, growth of 23% year-over-year. This growth reflects the diligence and execution we have employed over the last several years, building for opportunities we see ahead. Sometimes those opportunities are clearly visible many years in advance and others require us to be nimble and engage with our customers in real time to ensure we build and deliver what they need to be successful.
Frequently Asked Questions About TWST
When is Twist Bioscience's next earnings date?
Twist Bioscience's next earnings report is expected for Feb 1, 2027.
Did TWST beat earnings estimates last quarter?
Yes. Twist Bioscience reported EPS of -$0.32 for the quarter ended Sep 30, 2026, above the -$0.43 estimate, a 25.58% surprise.
What EPS do analysts expect from TWST next quarter?
The consensus EPS estimate for Twist Bioscience for the quarter ending Dec 31, 2026 is -$0.14 from 3 analysts, with estimates from -$0.31 to -$0.04.
How often does TWST beat earnings estimates?
Twist Bioscience beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +3.72%.
TWST pages: Overview, Earnings, Forecast, Financials, Competitors, Government Contracts